Sino-US Laekna has announced that it has received clinical trial clearance from the US Food and Drug Administration (FDA) for its LAE102 antibody. The drug is set to be assessed as a potential treatment for non-small cell lung cancer (NSCLC). This achievement marks LAE102 as Laekna’s first internally-discovered drug candidate to obtain IND clearance, showcasing the company’s capabilities in internal drug discovery.
LAE102: A Selective Monoclonal Antibody with Broad Regulatory Effects
LAE102 is a potent and selective monoclonal antibody that targets a novel, undisclosed mechanism with regulatory effects on various biological processes. These include tumor growth, immune activation, muscle regeneration, and hematopoietic development. The antibody’s multifaceted action highlights its potential in addressing complex diseases such as NSCLC, where multiple pathways may contribute to disease progression.-Fineline Info & Tech
